The Age-Related Macular Degeneration Market is being driven by High prevalence of AMD
The Age-Related Macular Degeneration Market is expected to grow at a CAGR of 7.3% during 2024 and 2029. During this period, the market is also expected to show a growth of USD 7368.8 million. In the dynamic global Age-Related Macular Degeneration (AMD) market, strategic collaborations among industry players are a significant trend, fueling innovation and broadening treatment availability. With the AMD prevalence increasing due to aging populations globally, pharmaceutical companies, biotech firms, and medical device manufacturers are forming alliances to expedite research, optimize clinical trials, and enhance therapeutic solutions. These partnerships often encompass co-development of groundbreaking biologics, gene therapies, and advanced drug delivery systems, aiming to enhance outcomes for both dry and wet AMD. Notably, collaborations between academic institutions and industry partners are fostering cross-functional innovation, integrating advanced retinal imaging, artificial intelligence diagnostics, and personalized medicine into AMD care.
Get more information on Age-Related Macular Degeneration Market by requesting a sample report
The market is segmented based on
According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows:
However, the market also witnesses some limitations, which are as follows:
Rich Experience: 20+ years leading global market research, trusted insights across industries.
Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.
Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
211 |
|
Base year |
2024 |
|
Historic period |
2019-2023 |
|
Forecast period |
2025-2029 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 7.3% |
|
Market growth 2025-2029 |
USD 7368.8 million |
|
Market structure |
fragmentation |
|
YoY growth 2024-2025(%) |
6.7 |
|
Key countries |
US, Canada, UK, China, Germany, France, Italy, Japan, India, and Brazil |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Find out which segment is leading the market by accessing the free PDF report
The Age-Related Macular Degeneration (AMD) market encompasses various aspects of this degenerative eye condition, including the progression of both dry and wet AMD, the implementation of early detection methods, identification of risk factors such as genetic predisposition and lifestyle modifications, patient management, and disease monitoring. Treatment options range from traditional methods like wet AMD treatment, to innovative approaches such as neuroprotection strategies, regenerative medicine, and targeted therapies. Clinical outcome measures, diagnostic imaging, therapeutic interventions, and drug delivery systems are essential components of effective AMD management. Personalized medicine, complementary therapies, and patient support groups also play a crucial role. Ongoing research advancements and clinical guidelines aim to improve best practices and management protocols for this disease burden.
The Age-Related Macular Degeneration (AMD) market falls under the broader global pharmaceuticals industry, encompassing entities involved in the research and development (R&D) or production of various drug classes, including generic and non-generic medicines, as well as veterinary drugs. According to Technavio, the healthcare market size is determined by the consolidated revenue generated by manufacturers and providers of medical equipment, consumables, pharmaceuticals, biotechnology, and life sciences tools and services. The expansion of the global pharmaceuticals market will be fueled by several key factors, among which is the increasing global population aging. By 2050, approximately one-quarter of the US population and by 2030 in Europe are projected to surpass the age of 60 years. This demographic shift will lead to a substantial rise in the prevalence of age-related conditions, such as photoreceptor degeneration, retinal pigment epithelium dysfunction, drusen formation, and choroidal neovascularization, thereby driving the demand for AMD treatments.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
